Department of Ultrasound, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 32# W.Sec 2,1st Ring Rd, 610072, Chengdu, China.
Department of Breast Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 610072, Chengdu, China.
Cancer Imaging. 2021 Mar 12;21(1):28. doi: 10.1186/s40644-021-00397-4.
This study aimed to explore the sentinel lymph node (SLN) identification rate in breast cancer by subcutaneous and intradermal injection of ultrasound contrast agent in the mammary areola region, compared to the results achieved with methylene blue (MB).
A total of 390 breast cancer patients with planned sentinel lymph node biopsy from our breast surgery department from July 2017 to February 2019 were enrolled. All patients were subjected to preoperative contrast-enhanced ultrasound (CEUS), that involved an intracutaneous injection of 1 mL ultrasonic contrast agent (UCA) at 3 and 6 o 'clock, as well as a subcutaneous injection of 1 mL UCA at 9 and 12 o'clock. The enhanced lymph nodes along the enhanced lymphatic vessels from the mammary areola were traced. The number of enhanced lymph nodes were recorded, and an ultrasound-guided injection of 1:10 diluted carbon nanoparticles were used to mark all first site enhanced lymph nodes (i.e., SLNs). An intraoperative dye method (MB) was used to track the SLNs and the results were compared with the CEUS findings.
Among the 390 cases of breast cancer, enhanced SLNs were observed in 373 patients after an injection of UCA with an identification rate of 95.64 % (373/390), compared to the identification rate of 92.05 % (359/390) using the intraoperative MB. The difference between the two methods was statistically significant (P = 0.016). And among the 390 patients, a total of 808 enhanced lymph nodes were traced by preoperative CEUS, with a median of 2 (1,3). A total of 971 blue-stained lymph nodes were traced using the intraoperative MB, with a median of 2 (2,3), indicating a statistically significant difference (p < 0.001).
Intradermal and subcutaneous injections of UCA in the mammary areola region may have clinical application value for the identification and localization of SLNs in breast cancer patients. The identification rate is higher than that of blue dye method, which can be used as a new tracer of sentinel lymph node biopsy and complement other staining methods to improve the success rate.
本研究旨在探讨乳晕皮下及皮内注射超声造影剂在乳腺癌前哨淋巴结(SLN)识别中的应用,与亚甲蓝(MB)法比较。
回顾性分析 2017 年 7 月至 2019 年 2 月我院乳腺外科行 SLN 活检的 390 例乳腺癌患者的临床资料。术前均行超声造影检查(CEUS),于乳晕 3、6 点行皮内 1ml 超声造影剂(UCA)注射,9、12 点行乳晕皮下 1mlUCA 注射,沿乳腺淋巴管增强区追踪增强的淋巴结,记录增强淋巴结数量,用超声引导下注射 1:10 稀释碳纳米粒子对所有第一站增强的淋巴结(即 SLN)进行标记。术中采用 MB 法追踪 SLN,并与 CEUS 结果进行比较。
390 例乳腺癌患者中,UCA 注射后观察到 373 例增强 SLN,识别率为 95.64%(373/390),术中 MB 法识别率为 92.05%(359/390),两种方法比较差异有统计学意义(P=0.016)。390 例患者术前 CEUS 共追踪到 808 个增强淋巴结,中位数为 2(1,3)个,术中 MB 法共追踪到 971 个蓝色染色淋巴结,中位数为 2(2,3)个,差异有统计学意义(P<0.001)。
乳晕皮下及皮内注射 UCA 对乳腺癌患者 SLN 的识别和定位具有临床应用价值,识别率高于 MB 法,可作为 SLN 活检的新示踪剂,与其他染色方法互补,提高成功率。